De Burlo Group Inc Supernus Pharmaceuticals, Inc. Transaction History

De Burlo Group Inc

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2018 Nov 08, 2018	SELL	$42.7 - $56.55 $1.56 Million - $2.06 Million	-36,500 Closed	0 $0
Q2 2018 Aug 10, 2018	BUY	$44.1 - $59.85 $1.61 Million - $2.18 Million	36,500 New	36,500 $2.18 Million

260

57.3M

84.1K

61.2K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.39B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of De Burlo Group Inc, based on Form 13F filings with the SEC.

Stay updated on De Burlo Group Inc with notifications on news.